For male carriers of BRCA1/2 pathogenic variants, recommendations consist of yearly screening with a digital rectal exam and prostate-specific antigen (PSA) blood test initiated by age 40–45 however limited data exists to support the effectiveness of additional screening (breast cancer) (National Comprehensive Cancer Network (NCCN), 2021a; Gao et al., 2019). Here, KLK3 is linked to breast cancer.